In lung cancer, mutations in the SMARCA4 gene account for 12% of non-oncogene-addicted lung adenocarcinomas, while 5% of gene mutations occur concurrently in oncogenic lung adenocarcinomas (1). Here, SMARCA4 is linked to lung adenocarcinoma.